Device, method, system and application thereof for diagnosing lymphatic metastasis of cervical cancer
The risk of lymphatic metastasis of cervical cancer was evaluated through the combination of biomarkers of resting thiol oxidase-1, paraoxase-1 and keratin 6A, and the problem of insufficient sensitivity of evaluation methods in the prior art was solved, and the further development of the Accurate lymphatic metastasis assessment and treatment decisions.
Patent Information
- Application Number
- CN202410929609.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-07-11
AI Technical Summary
The existing cervical cancer lymphatic metastasis assessment methods have low sensitivity, resulting in insufficient treatment in some patients and affecting the prognosis. A biomarker that is easy to predict and evaluate and its equipment, methods and systems are urgently needed.
Using the combination of three biomarkers, resting thiol oxidase-1, paraoxase-1 and keratin 6A, the ratio was calculated to evaluate the risk of cervical cancer lymphatic metastasis. Provide evaluation equipment and methods for accurate evaluation.
It improves the accuracy of early detection and evaluation of lymphatic metastasis in cervical cancer, reduces unnecessary treatment complications, and improves patient prognosis.
Smart Images

Figure CN118471335B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection technology, and specifically relates to equipment, methods, systems and applications thereof for diagnosing or evaluating cervical cancer lymph node metastasis. Background Art
[0002] Cancer is one of the major public health problems in the world, and the number of cancer patients is increasing every day. Among them, cervical cancer is one of the most common gynecological malignancies, and its main cause is persistent infection with high-risk human papilloma virus (HPV). According to estimates by the World Health Organization (WHO), there will be 604,000 new cases of cervical cancer and approximately 342,000 deaths worldwide in 2020.
[0003] In patients with cervical cancer, the main metastatic pathway is lymph node metastasis. Lymph node metastasis is an important factor affecting the prognosis of patients with cervical cancer. The 5-year overall survival (OS) of patients without lymph node metastasis is over 90%, and the 5-year OS of patients with lymph node metastasis is about 50%. Therefore, the evaluation and treatment of cervical cancer lymph node metastasis have received great attention. If patients with positive cervical cancer lymph node metastasis do not receive timely and appropriate treatment, they may relapse in a short period of time. Cervical cancer patients without lymph node metastasis also need to undergo a correct lymph node metastasis assessment before surgery. If they undergo unnecessary extensive lymph node resection, it will lead to some unnecessary related complications. Therefore, it is particularly important to check and accurately evaluate lymph node metastasis before surgery for patients with early cervical cancer or for patients in the middle and late stages who do not meet surgical indications.
[0004] At present, the methods for evaluating cervical cancer lymph node metastasis mainly include transabdominal / laparoscopic pathological sampling biopsy and imaging evaluation, such as computed tomography (CT) and magnetic resonance imaging (MRI). However, some patients may have low sensitivity to imaging examinations, which may lead to insufficient treatment of some cervical cancer patients with lymph node metastasis, thereby affecting the patient's prognosis. Therefore, there is an urgent need to find a biomarker that can easily predict and evaluate lymph node metastasis in cervical cancer patients and its corresponding equipment, methods, systems, etc., so as to predict and evaluate cervical cancer lymph node metastasis. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides a device, method, system and application thereof for evaluating cervical cancer lymph node metastasis.
[0006] To achieve the above object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides an evaluation device for evaluating lymph node metastasis of cervical cancer, characterized in that it comprises:
[0008] A data acquisition device, used to acquire detection data of an evaluation subject, wherein the detection data is a level value of a marker in a cervical cancer lymph node metastasis marker detected from human plasma of an evaluation subject suspected of having cervical cancer lymph node metastasis;
[0009] The data processing device is used to calculate the index value of the marker in the cervical cancer lymph node metastasis marker based on the detection data of the evaluation object, and then calculate whether the index value of the marker is within the risk range of the corresponding marker.
[0010] Herein, the level values of the markers are: resting sulfhydryl oxidase-1 is less than 0.59, paraoxonase 1 is less than 0.56, and the keratin 6A is less than 0.24.
[0011] Optionally, the device further comprises a detection device to detect the level of the marker.
[0012] The cervical cancer lymph node metastasis marker is one, two or a combination of three of the three markers, namely, resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A.
[0013] Exemplarily, the index value of the marker is the ratio between the level of the marker in the human plasma of the evaluation subject and the level of the marker in the human plasma without cervical cancer lymph node metastasis.
[0014] Preferably, the risk range of cervical cancer lymph node metastasis corresponding to the resting sulfhydryl oxidase-1 is an index value less than 0.59; the risk range of cervical cancer lymph node metastasis corresponding to the paraoxonase 1 is an index value less than 0.56; the risk range of cervical cancer lymph node metastasis corresponding to the keratin 6A is an index value less than 0.24.
[0015] Preferably, in the data processing device, when the index values of all markers in the cervical cancer lymph node metastasis markers are within their respective risk ranges, a corresponding cervical cancer lymph node metastasis assessment result prompt is given.
[0016] Preferably, the data acquisition device is an input device for inputting data or a communication device for reading data from an external data storage device through an interface.
[0017] In a second aspect, the present invention also relates to a computer-implemented method for evaluating whether lymph node metastasis occurs in a patient with cervical cancer.
[0018] In a third aspect, the present invention also relates to a computing system for evaluating whether lymph node metastasis occurs in a patient with cervical cancer.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The present invention provides a novel molecular marker that can be used to identify lymph node metastasis of cervical cancer, and can be used to construct a detection kit and an evaluation device for early detection, evaluation and prediction of lymph node metastasis of cervical cancer.
[0021] The biomarker for evaluating cervical cancer lymph node metastasis provided by the present invention is any combination of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A. The risk of cervical cancer lymph node metastasis is predicted by detecting the content of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A in plasma and combining the ratio, which is helpful to evaluate whether there is cervical cancer lymph node metastasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0023] Figure 1 OPLS-DA analysis of the proteomic results in the examples.
[0024] Figure 2 OPLS-DA analysis of the metabolomics results in the examples.
[0025] Figure 3 This is a volcano plot of differential proteins in the examples.
[0026] Figure 4 This is a volcano plot of differential metabolites in the examples.
[0027] Figure 5 4 is the ROC analysis result of cervical cancer lymph node metastasis biomarker in the example.
[0028] Figure 6 This is the ROC of the combined model of three markers of cervical cancer lymph node metastasis in the example.
[0029] Figure 7 The present invention is a block diagram of an integrated evaluation device for evaluating lymph node metastasis of cervical cancer according to an embodiment of the present invention.
[0030] Figure 8 The present invention is a flowchart of a computer-implemented method for evaluating cervical cancer lymph node metastasis according to an embodiment of the present invention. DETAILED DESCRIPTION
[0031] In order to make the above-mentioned purpose, features and advantages of the present invention more obvious and easy to understand, the specific implementation mode of the present invention is described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below. The technical features in each embodiment of the present invention can be combined accordingly without conflicting with each other.
[0032] Cervical cancer lymph node metastasis is a common cervical cancer metastasis phenomenon. The present invention provides corresponding biomarkers for cervical cancer lymph node metastasis, which are called cervical cancer lymph node metastasis markers.
[0033] Among them, the cervical cancer lymph node metastasis marker is one or more combinations of resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A.
[0034] It should be noted that the resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A in the present invention are all known proteins in the human body. The protein IDs thereof in the public protein database uniprot are shown in Table 1. Specifically: the English name of resting sulfhydryl oxidase-1 is Sulfhydryl oxidase 1, and the accession number in the protein database uniprot is O00391. The English name of paraoxonase-1 is Paraoxonase-1, and the accession number in the protein database uniprot is P27169. The English name of keratin 6A is Keratin 6A, and the accession number in the protein database uniprot is P02538.
[0035] Quiescent sulfhydryl oxidase-1 (QSOX1) is an enzyme that catalyzes redox reactions and plays an important role in the cell's internal and external environment. It catalyzes the oxidation of free sulfhydryl groups (i.e., groups containing sulfhydryl groups) to form disulfide bonds. This process helps fold and form proteins within cells and regulates the formation and stability of matrices in the cell's external environment. QSOX1 plays a key role in the redox balance within cells and is also closely related to the occurrence and development of some diseases, especially cancer.
[0036] Paraoxonase-1 (PON1) is an antioxidant enzyme that plays a key role in maintaining the oxidation-antioxidation balance in the body. It has been found that PON1 is associated with systemic oxidative stress and cardiovascular events, but there are few reports that it is associated with lymphatic metastasis of cervical cancer or can be used as a biomarker for lymphatic metastasis of cervical cancer.
[0037] Keratin 6A (KRT 6A) is a member of the keratin family and a cytoskeletal protein. It is mainly found in keratinized tissues such as skin, hair, and nails, and plays a role in maintaining cell morphology and mechanical support. Keratin 6A is highly expressed in the epidermis. Its main function is to provide structural support for cells and protect cells from damage by the external environment. It also participates in regulating the proliferation and differentiation of keratinocytes. In certain diseases such as skin diseases and cancers, the expression level of Keratin 6A may change, which is related to the occurrence and development of the disease.
[0038] Table 1 Protein IDs and Chinese and English names
[0039]
[0040] It should be noted that among the above-mentioned cervical cancer lymph node metastasis markers, any one of the three markers can be used alone as the basis for evaluating cervical cancer lymph node metastasis. However, since a single marker may be misjudged, it is preferred to use a combination of the three markers as cervical cancer lymph node metastasis markers to evaluate cervical cancer lymph node metastasis.
[0041] As a preferred embodiment of the present invention, the cervical cancer lymph node metastasis marker used to evaluate cervical cancer lymph node metastasis is a combination of three markers: resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A.
[0042] In another embodiment of the present invention, there is provided a reagent for detecting the above-mentioned cervical cancer lymph node metastasis marker (a single marker or a combination of multiple markers) for use in preparing an evaluation kit or detection device for evaluating cervical cancer lymph node metastasis. It should be noted that, since the above-mentioned cervical cancer lymph node metastasis marker may be a single marker or a combination of multiple markers, the corresponding evaluation kit or detection device may also be an evaluation kit or detection device for a single marker, or a combination of evaluation kits or detection devices for multiple markers.
[0043] It should be noted that the reagents contained in the specific kit of the present invention can be set according to the detection method of each marker. These three markers are all known substances, and corresponding detection methods are widely available in the prior art. Therefore, the means and reagents for detecting the above markers (a single marker or a combination of multiple markers) can be selected with reference to the prior art, and the corresponding evaluation kit or detection device can be constructed according to the prior art.
[0044] ELISA is a commonly used biomarker detection method that uses specific antibodies to bind to the biomarker to be detected, and then produces a measurable signal through an enzyme reaction. The ELISA method has high sensitivity and specificity and can be applied to the detection of a single marker or multiple markers.
[0045] Immunofluorescence analysis uses fluorescently labeled antibodies to bind to the biomarker to be detected, and detects the intensity of the fluorescent signal through a fluorescence microscope or a fluorescence photometer to quantitatively analyze the presence of the biomarker.
[0046] Mass spectrometry can accurately quantify biomarkers, including proton nuclear magnetic resonance (NMR) and mass spectrometry (MS), which can provide very precise molecular structure and relative content information.
[0047] PCR technology can be used to detect the transcribed RNA of biomarkers. The RNA or its fragments to be detected are amplified by PCR, and then quantitatively analyzed by gel electrophoresis or real-time fluorescence quantitative PCR.
[0048] Protein chip technology can detect multiple biomarkers simultaneously by fixing multiple antibodies on the chip surface, which are then bound to proteins in the sample to be tested (such as plasma), and finally the biomarkers are detected through fluorescent or radioactive labeled signals.
[0049] Exemplarily, considering detection efficiency and convenience, the kit may be an ELISA kit.
[0050] It should be noted that, generally speaking, the same evaluation subject may only suffer from cervical cancer lymph node metastasis at a certain moment, so the above-mentioned evaluation kit or detection device in the present invention can only be used to detect three markers of cervical cancer lymph node metastasis.
[0051] In another embodiment of the present invention, there is provided a use of the above biomarker (single marker or a combination of multiple markers) in the evaluation of cervical cancer lymph node metastasis for non-disease diagnosis or treatment purposes. The evaluation of cervical cancer lymph node metastasis for non-disease diagnosis or treatment purposes can be used for scientific research, non-medical commercial detection or testing, etc.
[0052] For example, biomarkers of cervical cancer lymph node metastasis can be used to study the disease mechanism, pathophysiological process and potential therapeutic targets. By analyzing the changes in these markers during the course of the disease, we can gain a deeper understanding of the development and metastasis mechanism of the disease and provide a deeper understanding for the prevention and treatment of the disease.
[0053] Biomarkers also play an important role in the drug development process. They can be used as indicators for drug efficacy evaluation to help researchers evaluate the safety and effectiveness of new drugs. By monitoring the effects of drugs on biomarkers, potential drug toxicity and adverse reactions can be detected early, and the adjustment and optimization of drug dosage can be guided.
[0054] Biomarkers can also be used in individual health management and preventive medicine. By regularly monitoring specific biomarkers, changes in individual health status can be detected in a timely manner, the risk of disease can be predicted, and appropriate health management measures can be taken, such as adjusting lifestyle, dietary habits or drug treatment, to maintain health and delay disease progression.
[0055] Biomarkers can be used to assess the impact of lifestyle on health. By monitoring changes in these markers, the impact of different lifestyles on health can be assessed, and individuals can be guided to take appropriate lifestyle intervention measures, such as losing weight, quitting smoking, increasing exercise, etc., to improve health and reduce disease risks.
[0056] In another embodiment of the present invention, there is provided an evaluation device for evaluating lymph node metastasis of cervical cancer, comprising:
[0057] A data acquisition device is used to acquire the test data of the evaluation object. The test data is the level value of the above-mentioned cervical cancer lymph node metastasis marker (a single marker or a combination of multiple markers) detected from the human plasma of the evaluation object suspected of having cervical cancer lymph node metastasis;
[0058] A data processing device is used to calculate the index value of the marker based on the detection data of the evaluation object, wherein the index value of the marker is the ratio between the level value of the marker in the human plasma of the evaluation object and the level value of the marker in the human plasma of a patient without cervical cancer metastasis, and then determine whether the calculated index value of the marker is within the risk range of the corresponding marker; if among all the cervical cancer lymph node metastasis markers, there is a situation where the index value of one or more markers is within the risk range of cervical cancer lymph node metastasis, then a corresponding cervical cancer lymph node metastasis assessment result prompt is given.
[0059] It should be noted that the risk range of each marker in the present invention needs to be obtained by statistical analysis based on the marker index values of different populations in a large amount of experimental data, so that the risk range can distinguish patients with cervical cancer lymph node metastasis from patients with cervical cancer without metastasis. As a preferred embodiment of the present invention, if the combination of three markers is used as the evaluation basis, through the statistical analysis of a large amount of experimental data, their respective risk ranges are as follows:
[0060] The risk range of resting sulfhydryl oxidase-1 indicating lymphatic metastasis of cervical cancer is an index value less than 0.59; the risk range of paraoxonase 1 indicating lymphatic metastasis of cervical cancer is an index value less than 0.56; the risk range of keratin 6A indicating lymphatic metastasis of cervical cancer is an index value less than 0.24. Of course, the risk ranges of the above three markers are only recommended ranges in the present invention, and those skilled in the art can also select some of them for use according to actual conditions, or use them after further optimization and adjustment.
[0061] In addition, the inventors of the present invention have discovered three markers, but in actual use, it is not necessary to include all the markers. For example, one or more of the three can be selected. However, for cervical cancer lymph node metastasis, if the three markers all include multiple markers for risk range judgment, theoretically, any marker that falls within its risk range can be regarded as a risk of cervical cancer lymph node metastasis. However, in actual application, in order to reduce the false detection rate, the index values of the markers included in the cervical cancer lymph node metastasis markers all fall within the risk range of cervical cancer lymph node metastasis, which indicates the risk of cervical cancer lymph node metastasis.
[0062] That is to say, in the above data processing device, it can be set that when the index values of all markers in the cervical cancer lymph node metastasis markers fall within their respective risk ranges, the corresponding cervical cancer lymph node metastasis assessment result prompt is given. If any of all the markers included in the risk range assessment is not within its corresponding risk range, the cervical cancer lymph node metastasis assessment result prompt may not be given.
[0063] Of course, in other embodiments, corresponding proportional risk levels can also be set according to the number of markers within the risk range. Even if there are markers that are not within the risk range, different risk levels can be given accordingly to facilitate the assessment of the risk level and provide a reference for clinical practice. For example, for cervical cancer lymph node metastasis markers, there are a total of 3 markers included in the risk range judgment, and a total of 3 risk levels are set. If N (N≤3) of the markers fall within the risk range, it indicates that there is an Nth risk level for cervical cancer lymph node metastasis. The larger N is, the greater the risk of cervical cancer lymph node metastasis.
[0064] It should be noted that the data acquisition device is an input device for inputting data or a communication device for reading data from an external data storage device through an interface. When an input device is used, the data detected by the external device can be input into the evaluation device, and then the evaluation result is given. When a communication device is used, the corresponding external data storage device can be a data storage device on a device for automatically measuring the aforementioned biomarkers. The evaluation device of the present invention can be integrated in the automated measurement device of the biomarker, so as to directly output the evaluation result after the measurement is completed, and realize an integrated detection and evaluation function.
[0065] The present invention also relates to a computer-implemented method for evaluating whether a cervical cancer patient has lymph node metastasis, the method comprising the following steps:
[0066] a) reading the test data of a cervical cancer patient, wherein the test data is the level value of one or a combination of cervical cancer lymph node metastasis markers, resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A, detected from human plasma of an evaluation subject suspected of having cervical cancer lymph node metastasis;
[0067] b) data processing, to calculate the index value of the marker according to the level value of step a), wherein the index value of the marker is the ratio between the level value of the marker in the human plasma of the evaluation subject and the level value in the human plasma of the patient without cervical cancer metastasis, and then determine whether the calculated index value of the marker is within the risk range of the corresponding marker;
[0068] c) Outputting the evaluation result. For example, if there is a situation where the index value of one or more markers is within the risk range of cervical cancer lymph node metastasis, a corresponding evaluation result prompt of cervical cancer lymph node metastasis is given.
[0069] As a preferred embodiment of the present invention, if the combination of three markers is used as the basis for evaluation, the risk ranges of each marker are as follows:
[0070] The risk range of resting sulfhydryl oxidase-1 indicating lymph node metastasis of cervical cancer is less than 0.59; the risk range of paraoxonase 1 indicating lymph node metastasis of cervical cancer is less than 0.56; the risk range of keratin 6A indicating lymph node metastasis of cervical cancer is less than 0.24.
[0071] The present invention also provides a computer system, which executes the following steps:
[0072] a) calculating the ratio between the level of the marker in the plasma of the evaluation subject suspected of having cervical cancer lymph node metastasis and the level of the marker in the human plasma of the cervical cancer patient without lymph node metastasis, wherein the marker is one or a combination of resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A;
[0073] b) Determine whether the calculated indicator value of the marker is within the preset risk range;
[0074] c) Outputting the judgment result of step b) and optionally giving a risk prompt. For example, if there is a situation where the index value of one or more markers is within the risk range of cervical cancer lymph node metastasis, a corresponding cervical cancer lymph node metastasis assessment result prompt is given.
[0075] The present invention further demonstrates the selection principle, process and effect of the above-mentioned biomarkers through a specific example below, so that those skilled in the art can understand the essence of the present invention.
[0076] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art. The reagents used in the present invention are all analytical grade or above. The chromatographic column used is model: Acclaim Pep Map100 C18 column, manufacturer: Thermo; the liquid chromatograph is model: EASY-nLC 1200, manufacturer: Thermo.
[0077] Example 1: Selection of biomarkers
[0078] Plasma samples were obtained from 40 participants. These 40 participants included 25 patients with cervical cancer without lymph node metastasis and 15 patients with cervical cancer with lymph node metastasis. Blood was collected from the elbow vein in EDTA anticoagulation tubes, gently inverted to mix, centrifuged at 1600g for 10 min at 4°C, and the supernatant was collected after centrifugation. The supernatant was transferred to a 1.5 ml centrifuge tube and centrifuged at 13000g for 2 min at 4°C. The supernatant was collected and divided into multiple centrifuge tubes. After the collected plasma was marked, it was immediately transferred to -80°C for storage in the dark to avoid repeated freezing and thawing.
[0079] Reagents used in this example: formic acid, methanol, ammonium formate, ammonium bicarbonate, acetonitrile, dithiothreitol (DTT), iodoacetamide (IAM).
[0080] 1. Targeting protein markers
[0081] Plasma samples were subjected to high-abundance protein removal. After the sample protein concentration was determined, 100 μg of blood samples were purified, and then the purified samples were subjected to reductive alkylation. The specific operation steps are as follows: high-abundance protein removal, protein purification, enrichment quality control, and proteolysis. The resulting peptides were then desalted on ZipTip Pipette Tips (Merck, Germany), dried under vacuum centrifugation, and stored at -80°C until detection.
[0082] Proteomic analysis was performed using nano-HPLC EASY-nLC 1200 (Thermo Fisher, USA) coupled with high-resolution mass spectrometer Orbitrap Exploris 480 (Thermo Fisher, USA). The chromatographic column was AcclaimPep Map 100 C18 column (75 μm inner diameter, 2 μm column particle size, approximately 25 cm column length). Separation was performed at a flow rate of 300 nL / min using the following effective gradient: 0-1.0 min, 3%-35% solution B (98% acetonitrile, 0.1% formic acid); 1-56 min, 35%-95% solution B; 56-59 min, 95% solution B; 59-65 min, 95%-3% solution B. The column temperature was maintained at 40°C, and the sample manager temperature was set at 4°C. The end of the nanoliter liquid phase separation was directly connected to the mass spectrometer and detected according to the following parameters. The peptides separated by the liquid phase were ionized by the nano ESI source and then entered the tandem mass spectrometer Orbitrap Exploris 480 (ThermoFisher, USA) for DDA (Data Dependent Acquisition) mode mass spectrometry data acquisition.
[0083] 2. Targeting metabolite markers
[0084] First, metabolite extraction: After slowly thawing the plasma sample at 4°C, take 100μL and place it in a 1.5ml EP tube, add 300μL of extraction solution (methanol:acetonitrile = 2:1, v:v, -20°C pre-cooling), 10μL of internal standard 1 and 10μL of internal standard 2, vortex mix for 1min, let stand at -20°C for 30min, and centrifuge at 4°C, 16000g for 30min. After centrifugation, take 300μL of supernatant, place it in a freeze vacuum concentrator to dry, add 150μL of reconstitution solution (methanol:water = 1:1, v:v) for reconstitution, vortex shake, centrifuge at 14000g, 4°C for 15min, and take the supernatant and place it in the injection bottle. Take 15μL of the supernatant of each sample and mix it into a QC quality control sample to evaluate the repeatability and stability of the LC-MS analysis process.
[0085] Vanquish ultra-performance liquid chromatography (UPLC) (Thermo Fisher, USA) was then coupled with a high-resolution mass spectrometer (Orbitrap Exploris 480, Thermo Fisher, USA) to separate and detect metabolites.
[0086] 3. Bioinformatics analysis to find markers
[0087] Biomarkers are mainly obtained through bioinformatics analysis methods such as differential screening, random forest, and ROC analysis. The criteria for screening differences are mainly fold change ≥1.2 or ≤0.83. P The value was <0.05. Then, the ROC curve analysis of the differential proteins and metabolites was performed, and then combined with random forest sorting, the results were integrated to select the final biomarkers. According to the above bioinformatics analysis, three markers were screened as markers of cervical cancer lymph node metastasis, which are one or more combinations of resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A, and all three markers are proteins.
[0088] Figure 1 and Figure 2 The OPLS-DA results of the proteome and metabolome in this example are shown respectively. In the figure, Non-Met represents the cervical cancer non-metastasis group, and Met-Lymph represents the cervical cancer lymph node metastasis group. The OPLS-DA analysis chart reflects the overall distribution of samples in each group.
[0089] Figure 3 This is a volcano map of differential proteins between the cervical cancer non-metastasis group and the cervical cancer lymph node metastasis group. The volcano map shows the results of differential proteins in the cervical cancer lymph node metastasis group. Among them, a total of 58 proteins were screened, and there were significant differences in the patients with cervical cancer lymph node metastasis without recurrence and metastasis. Among these proteins, 31 were downregulated and 27 were upregulated.
[0090] Figure 4 This is a volcano diagram of the differential metabolism of the cervical cancer non-metastasis group and the cervical cancer lymph node metastasis group. The volcano diagram shows the results of the differential metabolites of the cervical cancer lymph node metastasis group. Among them, a total of 288 metabolites were screened to show significant differences between patients with cervical cancer lymph node metastasis and those without recurrence and metastasis. Among these metabolites, 183 were downregulated and 105 were upregulated.
[0091] Figure 5 This is the ROC curve (receiver operating characteristic curve) analysis of the three markers in the cervical cancer lymph node metastasis marker obtained by the bioinformatics analysis in this embodiment, that is, the receiver operating characteristic curve analysis. The sensitivity and specificity of the three markers in evaluating cervical cancer lymph node metastasis are evaluated by drawing ROC and calculating the area under the curve (AUC). The judgment criteria are as follows: when AUC < 0.5, it means that the evaluation is meaningless; when AUC = 0.5-0.7, it means that the evaluation accuracy is low; when AUC = 0.7-0.9, it means that the evaluation accuracy is medium; when AUC > 0.9, it means that the evaluation accuracy is high. That is, in the ROC curve, the AUC value is the area covered by the ROC curve. The larger the value, the higher the accuracy of the model prediction.
[0092] from Figure 5 It can be seen that the three markers screened in this example, keratin 6A, resting sulfhydryl oxidase-1 (QSOX1) and paraoxonase-1 (PON1), have a high accuracy rate for evaluating cervical cancer lymph node metastasis, among which the AUC value of keratin 6A (KRT6A) is 0.909, the AUC value of resting sulfhydryl oxidase-1 (QSOX1) is 0.907, and the AUC value of paraoxonase-1 (PON1) is 0.907. It shows that any one of the markers of resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A can be used to evaluate whether there is cervical cancer lymph node metastasis.
[0093] 4. Marker combination modeling using logistic regression
[0094] For the cervical cancer lymph node metastasis group, the three candidate biomarkers of cervical cancer lymph node metastasis obtained previously were combined to construct a logistic regression model, and ROC curve analysis and evaluation were performed. Figure 6 The results of ROC analysis of the three marker combination model for cervical cancer lymph node metastasis were presented, and the results showed that the AUC value of the biomarker combination was 0.973. Compared with the above single markers, the combination of resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A had better prediction accuracy.
[0095] Example 2: Further confirmation of biomarkers
[0096] The plasma samples of 10 other patients with cervical cancer lymph node metastasis were selected and the contents of three biomarkers, keratin 6A, resting sulfhydryl oxidase-1 (QSOX1) and paraoxonase-1 (PON1), were determined with reference to Example 1, and compared with the three biomarkers in the plasma of 10 patients with cervical cancer without lymph node metastasis. The difference standard was the fold change ≥ 1.2 or ≤ 0.83, P Value < 0.05.
[0097] The results showed that for any of the three biomarkers, 9 out of the 10 selected patients with cervical cancer lymph node metastasis had significant differences compared with the control group, that is, 9 positive patients.
[0098] According to the combined model analysis constructed in Example 1, and the index value of each marker is set as the ratio between the level value of the marker in the human plasma of the subject and the level value in the plasma of the patient without cervical cancer lymph node metastasis, the risk range of each marker is as follows: the risk range corresponding to resting sulfhydryl oxidase-1 indicating cervical cancer lymph node metastasis is an index value less than 0.59; the risk range corresponding to paraoxonase 1 indicating cervical cancer lymph node metastasis is an index value less than 0.56; the risk range corresponding to keratin 6A indicating cervical cancer lymph node metastasis is an index value less than 0.24. It was found that all 10 selected patients with cervical cancer lymph node metastasis fell into the risk range, indicating that the combination of the three biomarkers of the present invention has better accuracy than a single biomarker.
[0099] Example 3: Integrated evaluation device for evaluating cervical cancer lymph node metastasis
[0100] The evaluation device is an integrated evaluation device for evaluating cervical cancer lymph node metastasis, including a data acquisition module, a data processing module and an output module. The device is designed to determine the risk of cervical cancer lymph node metastasis by measuring the levels of resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A and according to certain standards. Figure 7 This is a block diagram of an integrated evaluation device for evaluating lymph node metastasis of cervical cancer according to an embodiment of the present invention. The device includes:
[0101] Data acquisition module:
[0102] The module includes an automated plasma sample processing device for extracting plasma from blood samples collected from patients and performing biomarker measurements.
[0103] The biomarkers were determined using ELISA technology, which has high sensitivity and accuracy.
[0104] Data processing module:
[0105] The data processing module consists of a high-performance computer equipped with dedicated biomarker analysis software.
[0106] This module is responsible for receiving the biomarker measurement results transmitted from the data acquisition module and analyzing and processing them according to preset standards.
[0107] Output Module:
[0108] The output module includes an LCD display and a printer.
[0109] The evaluation results are intuitively displayed to clinicians via an LCD screen, and detailed evaluation reports can be output via a printer.
[0110] Operation process:
[0111] Sample collection and processing:
[0112] Medical staff collect blood samples from patients and send them to the data acquisition module.
[0113] The data acquisition module automatically extracts plasma and measures biomarkers.
[0114] Data transmission and analysis:
[0115] The measurement results of the biomarkers are transmitted to the data processing module through the data transmission interface.
[0116] The data processing module analyzes the measurement results of biomarkers according to preset standards and calculates the index value of each marker.
[0117] Evaluation result output:
[0118] If the index values of all markers in the cervical cancer lymph node metastasis markers are within their respective risk ranges, the output module will display the prompt "High risk of cervical cancer lymph node metastasis".
[0119] If the indicator values of one or more markers fall outside the risk range of cervical cancer lymph node metastasis, the output module will display a prompt "Low risk of cervical cancer lymph node metastasis" and output a detailed evaluation report.
[0120] Marker risk range:
[0121] The risk range of resting sulfhydryl oxidase-1 indicating lymph node metastasis of cervical cancer is an index value less than 0.59.
[0122] The risk range of paraoxonase 1 indicating lymph node metastasis of cervical cancer is an index value less than 0.56.
[0123] The risk range of keratin 6A indicating lymph node metastasis of cervical cancer is an index value less than 0.24.
[0124] Advantages and applications:
[0125] The integrated design makes the equipment easy to use and convenient to operate.
[0126] High-performance computers and dedicated software ensure accurate data analysis and reliable evaluation results.
[0127] The combination of automated plasma processing and biomarker measurement technology improves assessment efficiency and accuracy.
[0128] The LCD display and printer of the output module provide a variety of output methods to meet the needs of different clinical environments.
[0129] The evaluation device of this embodiment provides a comprehensive evaluation tool for clinicians, which can be used to quickly and accurately evaluate cervical cancer lymph node metastasis and guide the patient's treatment plan.
[0130] Example 4: Computer-implemented method for evaluating cervical cancer lymph node metastasis
[0131] This method is used to evaluate whether cervical cancer patients have lymph node metastasis. It reads the patient's test data, including the level of cervical cancer lymph node metastasis markers, calculates the index value of the marker according to certain standards, and finally outputs the evaluation result. Figure 8 This is a flowchart of a computer-implemented method for evaluating cervical cancer lymph node metastasis according to an embodiment of the present invention. The method comprises the following steps:
[0132] Read the test data:
[0133] Levels of cervical cancer lymph node metastasis markers, including a combination of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A, were obtained from human plasma of evaluation subjects suspected of having cervical cancer lymph node metastasis.
[0134] Data processing:
[0135] Based on the read level values, an index value of each marker is calculated, which is a ratio between the level value of the marker in the human plasma of the evaluation subject and the level value of the marker in the human plasma of a patient without cervical cancer metastasis.
[0136] Determine whether the calculated indicator value of the marker is within the risk range of the corresponding marker.
[0137] Output evaluation results:
[0138] If the index values of all markers are within the risk range of cervical cancer lymph node metastasis, the corresponding evaluation result prompt of cervical cancer lymph node metastasis will be given.
[0139] Specific implementation steps:
[0140] Data reading:
[0141] Plasma samples from patients with cervical cancer were obtained through medical equipment, and the levels of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A were measured.
[0142] Data processing:
[0143] According to the measured level value, the index value of each marker is calculated. For example, the index value calculation formula of resting sulfhydryl oxidase-1 is: Index value =
[0144] (Level of resting sulfhydryl oxidase-1 in the plasma of the subjects) /
[0145] (Levels of resting sulfhydryl oxidase-1 in plasma of patients without lymphatic metastasis).
[0146] Determine whether the calculated index value of the marker is within the risk range of the corresponding marker, where the risk range corresponding to resting sulfhydryl oxidase-1 is an index value less than 0.59, the risk range corresponding to paraoxonase-1 is an index value less than 0.56, and the risk range corresponding to keratin 6A is an index value less than 0.24. The level value here can be the content or expression level.
[0147] Output evaluation results:
[0148] If the index values of the three markers are within the risk range, the evaluation result prompt of cervical cancer lymph node metastasis will be output.
[0149] Advantages and applications:
[0150] The automated data processing process reduces the errors caused by manual operation. The index values based on the three markers increase the accuracy and reliability of the assessment. It can quickly and accurately assess whether cervical cancer patients have lymph node metastasis and guide clinical treatment decisions.
[0151] Example 5: Computer system for evaluating lymph node metastasis of cervical cancer
[0152] The computer system executes a series of steps to process and analyze the test data of cervical cancer patients to evaluate whether the patients have lymph node metastasis and provide corresponding evaluation result prompts.
[0153] Method steps:
[0154] Calculate the index value of the marker:
[0155] Levels of cervical cancer lymph node metastasis markers, including a combination of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A, were obtained from the plasma of the evaluation subjects suspected of having cervical cancer lymph node metastasis.
[0156] The ratio of the level of each marker in the plasma of the evaluation subject to the level of each marker in the plasma of the cervical cancer patient without lymph node metastasis was calculated to obtain the index value of each marker.
[0157] Determine whether the indicator value is within the risk range:
[0158] The indicator value of each marker is judged to see whether it is within the preset risk range. The indicator values are compared and analyzed according to the risk range given in the claims.
[0159] Output evaluation results:
[0160] Based on the judgment result, the evaluation result of whether there is cervical cancer lymph node metastasis is output.
[0161] If the index values of three markers are within the risk range of cervical cancer lymph node metastasis, the corresponding assessment result prompt of cervical cancer lymph node metastasis will be given.
[0162] Specific implementation steps:
[0163] Data reading and processing:
[0164] Plasma samples from patients with cervical cancer were obtained through medical equipment, and the levels of resting sulfhydryl oxidase-1, paraoxonase-1, and keratin 6A were measured.
[0165] The index value of each marker is calculated. For example, the index value of resting sulfhydryl oxidase-1 is calculated as follows:
[0166] Index value =
[0167] (Level of resting sulfhydryl oxidase-1 in the plasma of subjects) / (Level of resting sulfhydryl oxidase-1 in the plasma of patients without lymph node metastasis).
[0168] risk assessment:
[0169] Determine whether the index value of each marker is within the preset risk range. For example, the risk range corresponding to resting sulfhydryl oxidase-1 is an index value less than 0.59, the risk range corresponding to paraoxonase-1 is an index value less than 0.56, and the risk range corresponding to keratin 6A is an index value less than 0.24.
[0170] Output:
[0171] Based on the risk assessment results, the assessment results of whether there is cervical cancer lymph node metastasis are output.
[0172] If the index values of three markers are within the risk range, the corresponding assessment result prompt of cervical cancer lymph node metastasis will be given.
[0173] Advantages and applications:
[0174] The system can automatically process test data and conduct a comprehensive evaluation based on the index values of multiple markers, thereby improving the accuracy and reliability of the evaluation results. It can quickly and accurately evaluate whether lymph node metastasis occurs in cervical cancer patients, providing an important reference for clinical treatment.
[0175] The computer system of this embodiment provides medical workers with an effective tool for evaluating the risk of lymph node metastasis in patients with cervical cancer and provides an important basis for personalized treatment.
[0176] The above-described embodiment is only a preferred solution of the present invention, but it is not intended to limit the present invention. A person skilled in the relevant technical field may make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.
[0177] The serial numbers of the above embodiments of the present invention are only for description and do not represent the advantages or disadvantages of the embodiments.
[0178] A person skilled in the art will understand that all or part of the steps to implement the above embodiments may be accomplished by hardware or by instructing related hardware through a program, and the program may be stored in a computer-readable storage medium, and the above-mentioned storage medium may be a read-only memory, a disk or an optical disk, etc.
[0179] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An evaluation device for evaluating lymph node metastasis of cervical cancer, characterized in that: include: A data acquisition device, used to acquire detection data of an evaluation subject, wherein the detection data is a level value of a marker in a cervical cancer lymph node metastasis marker detected from human plasma of an evaluation subject suspected of having cervical cancer lymph node metastasis; A data processing device, used to calculate the index value of a marker in the cervical cancer lymph node metastasis marker based on the detection data of the evaluation object, and then calculate whether the index value of the marker obtained is within the risk range of the corresponding marker; The cervical cancer lymph node metastasis marker is a combination of resting sulfhydryl oxidase-1, paraoxonase 1 and keratin 6A.
2. The evaluation device according to claim 1, characterized in that The device further comprises a detection device to detect the level of the marker.
3. The evaluation device according to claim 1, characterized in that The index value of the marker is the ratio between the level of the marker in the human plasma of the evaluation subject and the level of the marker in the human plasma without cervical cancer lymph node metastasis.
4. The evaluation device according to claim 1, characterized in that The risk range of the resting sulfhydryl oxidase-1 indicating lymph node metastasis of cervical cancer is an index value of less than 0.59; the risk range of the paraoxonase 1 indicating lymph node metastasis of cervical cancer is an index value of less than 0.56; the risk range of the keratin 6A indicating lymph node metastasis of cervical cancer is an index value of less than 0.
24.
5. The evaluation device according to claim 1, characterized in that In the data processing device, when the index values of all markers in the cervical cancer lymph node metastasis markers are within their respective risk ranges, a corresponding cervical cancer lymph node metastasis assessment result prompt is given.
6. The evaluation device according to any one of claims 1 to 4, characterized in that The data acquisition device is an input device for inputting data or a communication device for reading data from an external data storage device or a storage device of the detection device through an interface.
7. The evaluation device according to claim 6, characterized in that When a communication device is used, its corresponding external data storage device is a data storage device on a device for measuring biomarkers.
8. The evaluation device according to claim 6, characterized in that It is integrated into the automated measurement equipment for biomarkers, so that the evaluation results can be directly output after the measurement is completed, thus realizing an integrated detection and evaluation function.
9. A computer-implemented method for evaluating whether a cervical cancer patient has lymph node metastasis, the method comprising the following steps: a) reading the test data of cervical cancer patients, wherein the test data are the levels of cervical cancer lymph node metastasis markers resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A detected in human plasma of an evaluation subject suspected of having cervical cancer lymph node metastasis; b) data processing, to calculate the index value of the marker according to the level value of step a), wherein the index value of the marker is the ratio between the level value of the marker in the human plasma of the evaluation subject and the level value in the human plasma of the patient without cervical cancer metastasis, and then determine whether the calculated index value of the marker is within the risk range of the corresponding marker; c) Output the evaluation results.
10. The execution method according to claim 9, wherein in step c), if there is a situation where the index value of one or more markers is within the risk range of cervical cancer lymph node metastasis, a corresponding evaluation result prompt of cervical cancer lymph node metastasis is given.
11. The method according to claim 9, wherein in step b), if a combination of three markers is used as the basis for evaluation, the risk ranges of each marker are as follows: The risk range of resting sulfhydryl oxidase-1 indicating lymph node metastasis of cervical cancer is less than 0.59; the risk range of paraoxonase-1 indicating lymph node metastasis of cervical cancer is less than 0.56; the risk range of keratin 6A indicating lymph node metastasis of cervical cancer is less than 0.
24.
12. A computer system, comprising: a) calculating the ratio between the level of the marker in the plasma of the evaluation subject suspected of having cervical cancer lymph node metastasis and the level of the marker in the human plasma of the cervical cancer patient without lymph node metastasis, wherein the marker is a combination of resting sulfhydryl oxidase-1, paraoxonase-1 and keratin 6A; b) Determine whether the calculated indicator value of the marker is within the preset risk range; c) Output the judgment result of step b) and optionally give a risk prompt. If there is a situation where the index value of one or more markers is within the risk range of cervical cancer lymph node metastasis, a corresponding cervical cancer lymph node metastasis assessment result prompt is given.
